These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 14568971)

  • 1. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.
    Karanikas V; Lurquin C; Colau D; van Baren N; De Smet C; Lethé B; Connerotte T; Corbière V; Demoitié MA; Liénard D; Dréno B; Velu T; Boon T; Coulie PG
    J Immunol; 2003 Nov; 171(9):4898-904. PubMed ID: 14568971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
    Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
    J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
    van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
    J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
    Lonchay C; van der Bruggen P; Connerotte T; Hanagiri T; Coulie P; Colau D; Lucas S; Van Pel A; Thielemans K; van Baren N; Boon T
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14631-8. PubMed ID: 15452345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.
    Hanagiri T; van Baren N; Neyns B; Boon T; Coulie PG
    Cancer Immunol Immunother; 2006 Feb; 55(2):178-84. PubMed ID: 16187089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
    Connerotte T; Van Pel A; Godelaine D; Tartour E; Schuler-Thurner B; Lucas S; Thielemans K; Schuler G; Coulie PG
    Cancer Res; 2008 May; 68(10):3931-40. PubMed ID: 18483279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.
    Coulie PG; Karanikas V; Colau D; Lurquin C; Landry C; Marchand M; Dorval T; Brichard V; Boon T
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10290-5. PubMed ID: 11517302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
    Valmori D; Lévy F; Miconnet I; Zajac P; Spagnoli GC; Rimoldi D; Liénard D; Cerundolo V; Cerottini JC; Romero P
    J Immunol; 2000 Jan; 164(2):1125-31. PubMed ID: 10623865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
    Carrasco J; Van Pel A; Neyns B; Lethé B; Brasseur F; Renkvist N; van der Bruggen P; van Baren N; Paulus R; Thielemans K; Boon T; Godelaine D
    J Immunol; 2008 Mar; 180(5):3585-93. PubMed ID: 18292586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.
    Trakatelli M; Toungouz M; Lambermont M; Heenen M; Velu T; Bruyns C
    Cancer Gene Ther; 2005 Jun; 12(6):552-9. PubMed ID: 15665821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
    Zhang Y; Chaux P; Stroobant V; Eggermont AM; Corthals J; Maillère B; Thielemans K; Marchand M; Boon T; Van Der Bruggen P
    J Immunol; 2003 Jul; 171(1):219-25. PubMed ID: 12817001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.
    Ma W; Vigneron N; Chapiro J; Stroobant V; Germeau C; Boon T; Coulie PG; Van den Eynde BJ
    Int J Cancer; 2011 Nov; 129(10):2427-34. PubMed ID: 21207413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.
    Spaner DE; Astsaturov I; Vogel T; Petrella T; Elias I; Burdett-Radoux S; Verma S; Iscoe N; Hamilton P; Berinstein NL
    Cancer; 2006 Feb; 106(4):890-9. PubMed ID: 16404742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
    Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
    J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
    Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
    Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
    Coulie PG; Karanikas V; Lurquin C; Colau D; Connerotte T; Hanagiri T; Van Pel A; Lucas S; Godelaine D; Lonchay C; Marchand M; Van Baren N; Boon T
    Immunol Rev; 2002 Oct; 188():33-42. PubMed ID: 12445279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
    Zhang Y; Sun Z; Nicolay H; Meyer RG; Renkvist N; Stroobant V; Corthals J; Carrasco J; Eggermont AM; Marchand M; Thielemans K; Wölfel T; Boon T; van der Bruggen P
    J Immunol; 2005 Feb; 174(4):2404-11. PubMed ID: 15699177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.